MOR209/ES414 is a novel humanized BsAb which is designed to treat metastatic castration-resistant prostate cancer (mCRPC) by redirecting T cell cytotoxicity against prostate cancer cells expressing PSMA. Here, FOLH1 is linked to prostate carcinoma.